Abstract
In this study, a series of novel triazoline Schiff bases are designed and synthesized on a triazole-based AADHR_1 hypothesis pharmacophore model tailored to meet structural requirements for antibacterial activity. FT-IR, 1H NMR, and 13C NMR spectroscopy techniques confirmed molecular structures. Assessment of ADMET properties utilizing the pkCSM online tool unveiled encouraging pharmacokinetic profiles. Detailed Density Functional Theory (DFT) calculations showed significant electronic properties, delineating certain compounds as potent electron donors or acceptors. Docking studies unveil that, the compound 1-((1-(p-tolyl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxylic acid (2b) binded into the active site of the Penicillin-binding protein (PBP2a) of Methicillin-resistant Staphylococcus aureus (MRSA) with the docking score of -8.0 kcal/mol. Molecular dynamics simulations further corroborated the stability of the protein-ligand complex, emphasizing the compound 2b is enduring interaction at the MRSA protein's active site. Antibacterial assays against MRSA showed selective compounds exhibiting minimum inhibitory concentrations (MICs) of 20 µg/mL and Zone of inhibition up to 14 mm, highlighting their potential as effective antimicrobial agents against antibiotic-resistant bacteria. These findings collectively suggest the promising therapeutic prospects of the synthesized triazoline Schiff bases in combatting MRSA infections.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call